|
|
||||||||
1From Moorfields Eye Hospital, London, United Kingdom; 2Institute of Ophthalmology, University College London, London, United Kingdom; 3Laboratoire de Physiopathologie Cellulaire Moléculaire et de la Rétine, Inserm U592, Université Pierre et Marie Curie, Paris, France; the 5University Eye Hospital, Medical Centre Ljubljana, Ljubljana, Slovenia; and the 6Department of Ophthalmology, Prince of Wales Hospital, Randwick, NSW, Australia.
| Abstract |
|---|
|
|
|---|
METHODS. Patients underwent ophthalmic examination and functional testing including pattern ERG, full-field ERG, and long-duration and short-wavelength stimulation. Further tests were performed in some patients, including color contrast sensitivity (CCS), multifocal ERG, fundus autofluorescence imaging (FAI), optical coherence tomography (OCT), and fundus fluorescein angiography (FFA). Mutational screening of NR2E3 was undertaken in 13 patients.
RESULTS. The fundus appearance was variable, from normal to typical nummular pigment clumping at the level of the retinal pigment epithelium in older patients. Nine patients had foveal schisis, and one had peripheral schisis. Pattern ERG was abnormal in all patients. In all patients, ISCEV Standard photopic and scotopic responses had a similar waveform, the rod-specific-ERG was undetectable and the 30-Hz flicker ERG was markedly delayed with an amplitude lower than the photopic a-wave. Most ERG responses arose from short-wavelength–sensitive mechanisms, and a majority of patients showed possible OFF-related activity. Multifocal ERG showed relative preservation of central function, but reduced responses with increased eccentricity. Mutations were identified in NR2E3 in 12 of 13 patients including four novel variants.
CONCLUSIONS. The phenotype in ESCS is variable, both in fundus appearance and in the severity of the electrophysiological abnormalities. The ERGs are dominated by short-wavelength–sensitive mechanisms. The presence, in most of the patients, of possible OFF-related ERG activity is a finding not usually associated with S-cones.
Histopathologic data have been reported from one elderly patient with advanced disease.5 There was an absence of rods, but a two-fold increase in the cone population, most of which were thought to be S-cones. Fifteen percent of the cones expressed L/M-cone opsin including some which co-expressed S-cone opsin. The retina was highly degenerated and disorganized. Photoreceptors were found only in the central and far peripheral regions. Densely packed cones were intermixed with inner retinal neurons. The increased number of cones in ESCS is unique, since, as a group of disorders, the progressive retinal dystrophies are usually characterized by a loss of photoreceptors.
Mutations in the NR2E3 gene (also known as photoreceptor-specific nuclear receptor (PNR; OMIM 604485) have been found in both ESCS and Goldman-Favre Syndrome (GFS).6 7 8 A naturally occurring recessive NR2E3 mutation has also been identified in the rd7 mouse and has helped further to probe the disease process.9 10 11 12
NR2E3 encodes a ligand-dependent transcription factor that controls retinal progenitor cell fate.13 14 It promotes differentiation and survival of rod photoreceptors by differentially regulating transcription of rod- and cone-specific genes either directly or indirectly through interaction with other transcription factors, including CRX and NRL.14 15 16 17 Mutation in NR2E3 is thought to cause disordered photoreceptor cell differentiation, possibly by encouraging default from the rod photoreceptor pathway to the S-cone pathway, thereby altering the relative ratio of cone subtypes.5 14 18 19 However, to date, NR2E3 expression has been identified only in rod photoreceptors.6 10 13 15 16
The purpose of the present study was to review the detailed phenotype of a panel of patients with a diagnosis of ESCS and subsequently to characterize the proportion and nature of NR2E3 mutations in this cohort.
| Methods |
|---|
|
|
|---|
Each patient underwent full ophthalmic examination after providing informed consent. Full-field and pattern electroretinography (ERG and PERG) were performed with gold foil recording electrodes (HK-loop electrodes in patients 15 and 16) and incorporated the ISCEV Standards.20 21 A stimulus 0.6 log units stronger than the ISCEV standard flash was used to elicit the bright flash ERG, the better to demonstrate the dark-adapted a-wave.21 A light-emitting diode–based mini-Ganzfeld was used to elicit S-cone ERGs22 and ON and OFF responses. S-cone ERGs used a blue stimulus (445 nm, 80 cd/m2) on an orange background (620 nm, 560 cd/m2), with the same orange stimulus of 200-ms duration used with a green background (530 nm, 160 cd/m2) for ON and OFF responses from the L/M-cone systems. Stimulus duration for the blue stimulus was varied from 1 to 10 ms for short-duration flashes, and was 200 ms for the long-duration flashes used to examine ON and OFF responses. Further tests were performed in some patients including color contrast sensitivity (CCS, 9/19 patients), multifocal ERG (6/19), fundus autofluorescence imaging (FAI, 7/19), optical coherence tomography (OCT, 4/19) and fundus fluorescein angiography (FFA, 5/19). CCS was assessed according to previously described techniques.23 24
NR2E3 was screened for disease-causing mutations in all patients who consented to give blood samples (n = 13). Total genomic DNA was extracted from peripheral blood leukocytes (Nucleon II Biosciences kit; Scotlab Ltd., Strathclyde, UK). The gene NR2E3 is located on chromosome 15, arm q23, and has nine exons encoding a protein of 409 residues. Coding sequences and splice-junction sites of NR2E3 were amplified by polymerase chain reaction (PCR) in each individual by using the primer sequences and annealing temperatures shown in Table 1 . PCR reactions (50 µL) were performed as follows: 1 x NH4 reaction buffer (Bioline, London, UK), 1 mM MgCl2, 200 µM each dNTP, 10 picomoles each of forward and reverse primers, 200 ng to 1 µg DNA, and1 U Taq polymerase (BioTaq; Bioline). After resolution on a 1% (wt/vol) low-melting-temperature agarose gel, the products were excised and eluted. Direct sequencing of PCR products was performed on a genetic analyser (model 3100; Applied Biosystems [ABI], Warrington, UK) using the original PCR primers in the sequencing reactions. The sequence was examined for alterations using sequencing analysis (Prism with GeneWorks software; ABI). GenBank sequences were used to construct an alignment of nuclear receptor sequences to analyze the evolutionary conservation of the corresponding amino acid positions. Sequences were aligned with the software (GeneWorks software; ABI).
|
| Results |
|---|
|
|
|---|
|
Vitreous cells were present in all patients. Two subjects exhibited more prominent vitreous changes including vitreous opacities, haze, and veils. The fundus appearance varied extensively between patients (Fig. 1) . The youngest subject had normal appearing fundi. Six patients had subtle to mild pigmentary changes with focal hyperpigmentation (Figs. 1a 1b 1c) , with one of these subjects having small yellow-white dots at the posterior pole. The most distinctive ophthalmoscopic feature was nummular pigmentary deposition at the level of the RPE, usually located in the mid periphery along the vascular arcades and often associated with RPE atrophy (Figs. 1a 1d 1e 1f) . This characteristic pigmentary clumping was noted in 12 of 19 patients. In addition, yellow-white deposits were also present in areas of marked pigmentary abnormalities or within the posterior pole (Fig. 1d) . Foveal schisis-like changes were observed in nine patients. OCT was performed in four of those patients and demonstrated foveal cyst formation (Fig. 1b) . Cystoid macular edema was originally diagnosed on clinical examination in three of nine patients. Oral acetazolamide therapy produced no documented improvement. Subsequently, these patients had FFA, which showed no leakage (Fig. 2) , suggesting that the cystoid changes were more likely to be secondary to schisis than to edema. One patient had peripheral schisis (Fig. 1d) .
|
|
Functional Evaluation
The functional findings are summarized in Table 3 Color contrast sensitivity (CCS) was tested in nine patients. Two had normal color vision. In one, a generalized dyschromatopsia was revealed, whereas six of nine patients demonstrated relative tritan axis sparing and moderately elevated protan and deutan thresholds.
|
All patients had pathognomonic ERG waveforms (Figs. 3 4) . The rod-specific ERG was undetectable; the ERG response to a standard single flash had similar waveforms under photopic and scotopic conditions; and the 30-Hz flicker ERG was both delayed and of lower amplitude than the single-flash photopic ERG a-wave. Such findings establish the diagnosis with or without the use of specific short-wavelength stimulation. Included in Table 3 is an evaluation of each patient based on the dark-adapted bright flash a-wave as a percentage of the lower limit of normal (the absolute normal values differ between the two units from which the patients have been ascertained). However, it is stressed that the scotopic a-wave in ESCS is likely to be arising from dark-adapted short-wavelength–sensitive cones (as opposed to the rod-dominated a-wave in a normal retina), is also of markedly longer peak time, and the use of this measure is not intended to imply physiological equivalence, merely to allow an estimate of the overall severity of the disorder in each patient. ERG amplitudes showed high variability between patients related to the severity of degeneration, with older patients tending to have the more severe abnormalities.
|
|
|
Visual field data have been described when available; these data are not available for all patients.
NR2E3 Mutation Screening
Screening of the nine coding exons of NR2E3 was performed in 13 of 19 patients. Mutations were identified in 12 of 13 subjects: with 8 subjects being homozygous, 3 having compound heterozygous mutations, and 1 heterozygous individual having no identified second mutation. Screening of NR2E3 yielded eight sequence variants that most likely represent disease-causing mutations, including four novel mutations (Table 4) . Four previously reported mutations were identified, a splice acceptor intron 1 mutation,6 7 8 the Arg311Gln and Arg104Trp substitutions,6 7 8 and the 481delA frameshift mutation.8 The four novel mutations were two splice acceptor variants (introns 1 and 8) and two missense mutations (Val49Met and Tyr81Cys).
|
A; exon 6;
45% of patients)6 was found as a heterozygous change in patient 4 (Fig. 6b) ; the Arg104Trp (R104W) substitution (500C
T; exon 3) was identified as a homozygous change in patients 9 and 10 (father and daughter, respectively; the mother was found to be heterozygous for R104W, being a first cousin and unaffected); and the frameshift mutation, T161fs (481delA; exon 4), as a homozygous change in patients 15 and 16 (brothers; Fig. 6c ). This frameshift mutation would generate a stop codon at position 178. The T161fs has been described only in the heterozygous state.8 The R311Q mutation is far less prevalent in the sample in our study than in previous investigations.6 8
|
A; exon 2; Fig. 6d ) was identified as a homozygous change in patient 3; and the Tyr81Cys (Y81C) substitution (242A
G; exon 2; Fig. 6e ) as a heterozygous change in patients 7 and 8 (sisters). Both Val49 and Tyr81 are conserved across other NR2E3 receptors, and neither missense mutation was found in a screen of 100 control chromosomes. V49M and Y81C are both located in the highly conserved DNA binding domain of NR2E3.
Two novel splice site mutations were identified: the first novel splice acceptor (3' splice) mutation is a C
G nucleotide change at the intron 1 splice site (IVS1-3C>G) (Figs. 6f 7) , identified as a homozygous change in patient 13. One of the most common previously reported mutations in NR2E3 is an A
C change at this same splice site.6 7 8 A mutation identified in the present cohort in both heterozygous and homozygous states (5/10 patients). The second novel splice acceptor mutation identified is at intron 8 (IVS8-1G>A; Figs. 6g 7 ), present as a homozygous change in patient 1. Neither novel splice acceptor mutation was found in a screen of 100 control chromosomes. The likely effect of the splice acceptor intron 1 and intron 8 mutations would be to cause aberrant splicing, resulting in either failure to remove these introns, or loss of exon 2 or 9, respectively, from the transcript as a result of splicing with the next intact splice acceptor site (Fig. 7) . The loss of exon 9 would require splicing to an acceptor site downstream of the coding sequence of the gene. A retained intron may lead to premature termination of translation and a truncated protein that is either nonfunctional or has reduced efficacy. Loss of exons will result in the absence in the protein of amino acid residues encoded by these regions and since exons 2 and 9 encode residues involved in DNA-binding and ligand-binding, respectively, a transcription factor of significantly reduced function would be predicted. However, the loss of exon 2 would also generate a frameshift as intron 1 interrupts codon 40 of exons 1 and 2 at position 1, whereas intron 2 interrupts codon 82 of exons 2 and 3 at position 2, thus generating a stop codon in exon 3 and most likely resulting in nonsense-mediated mRNA decay in the aberrant transcript and the complete absence of any protein.
|
T; exon 3) and G288G (864T
A; exon 6). | Discussion |
|---|
|
|
|---|
All subjects experienced nyctalopia at an early age. Visual acuity was variable from normal to severely reduced (3/60), but there was no correlation with age; some younger individuals had worse visual acuity than older patients. The presence of foveal schisis was often associated with poor visual acuity. The most common refractive error identified was hyperopia, with a variable degree of astigmatism, in keeping with previous reports.2 7 Longitudinal ERG data were available for some patients and suggested slowly progressive dysfunction with gradual deterioration of visual acuity and variable visual field constriction. Color contrast sensitivity testing revealed sparing along the tritan axis in 6 of 9 patients. The findings also suggested some residual L- and M-cone–mediated function in keeping with the available histopathologic data.5
Fundus examination revealed a highly variable retinal phenotype, ranging from normal to marked pigmentary abnormalities. The most typical ophthalmoscopic feature was the presence of nummular, mid-peripheral pigmentary deposits at the level of the RPE. This typical retinal appearance was associated with an absence of AF outside the vascular arcades on FAI, possibly relating to loss of photoreceptors in this region.5 A ring of relatively increased AF in the transitional area between the region of absent AF and the central zone of relatively normal AF was evident. The increased AF detected may be related to lipofuscin accumulation secondary to RPE–photoreceptor dysfunction in that area.27 28 Such rings have been described in the parafoveal region in both RP and cone–rod dystrophy (Robson AG, et al. IOVS 2005;46:ARVO E-Abstract 552).29 30 31 32 33 34 35 Foveal schisis documented by FFA, OCT, or RTA was present in nine patients, in keeping with previous findings.2
The typical nummular, mid-peripheral pigmentary changes are a useful clinical sign, but are not a consistent finding, being evident in 12 of 19 patients in the present series. Sharon et al.7 suggested that subtle pigmentary changes with white dots represent an early stage of the disease process, which progresses to the typical clumped retinopathy in later adulthood. The observation in the present cohort of a 72-year-old patient with only very subtle pigmentary changes does not support this suggestion and emphasizes the variability of fundus findings in ESCS. Furthermore, this nummular pigmentary retinopathy is not specific to ESCS, since similar fundus abnormalities have been reported in Bardet-Biedl syndrome,36 in RP with preserved para-arteriolar RPE (RP12, associated with mutation in CRB1),37 38 39 and in non-syndromic RP.7 40 The association of these nummular pigmentary deposits with white-yellow dots at the level of the RPE along the vascular arcades, focal hyperpigmentation within the arcades, and foveal or peripheral schisis is more suggestive of ESCS. Small hyperpigmented areas and white dots were also seen within the vascular arcades in some patients. These dots were associated with a focal increase in AF. These abnormalities may be related to those in the rd7 mouse, which harbors a homozygous deletion in NR2E3 and displays retinal white dots early in the disease process that histologically correspond to rosettes of dysplastic photoreceptors and which disappear with age.11 12
All subjects included in the study had typical electrophysiological findings of short-wavelength–sensitive pathway predominance, with severely reduced L- and M-cone function and no detectable rod ERGs.3 4 In addition, the ERG findings in all patients where they were detectable, were pathognomonic of ESCS: the rod-specific ERG was undetectable; the ERG to a standard flash was simplified and delayed, with a similar waveform under photopic and scotopic conditions; and, also of importance, the 30-Hz flicker was delayed and of lower amplitude than the single-flash photopic ERG a-wave, ESCS being the only disorder of which these authors are aware in which that is the case. Further, abnormally large, delayed, simplified waveform S-cone ERG responses (relative to the size of the conventional ERGs) were present in all patients tested, confirming the sensitivity to short-wavelength stimulation characteristic of the disorder, but not necessary in making the diagnosis. Responses to high-intensity, long-duration orange stimulus on a green background were severely subnormal in all patients, in keeping with reduced L/M-cone function. The amplitude of the ERG was variable across patients with a tendency toward lower amplitudes in older patients, some of whom had profound global ERG reduction, but in whom the findings were otherwise qualitatively similar. The absence of an EOG light increase can be related to the absence of rod photoreceptors.
The spatial extent and degree of mfERG preservation varied between patients and paralleled the PERG findings. Patients with normal amplitude central responses and paracentral sparing had higher amplitude PERG P50 components (e.g., cases 2 and 4), in keeping with a lesser degree of macular dysfunction, than those in which only the central mfERG showed sparing or relative sparing (e.g., case 5). Correlation between mfERGs and PERGs have been reported in cases of RP33 41 in which central photopic function is preserved in the presence of encroaching paracentral dysfunction. The current findings extend those previously described in a single case of ESCS in which mfERGs revealed greater peripheral than central abnormalities.42 The PERG data are noteworthy; the profound delay present in some patients is an unusual and novel observation.
The responses to long-duration stimulation using a blue flash with an orange background are of particular interest. The reduction in b-wave amplitude in most of the patients when stimulus duration was increased from 10 to 200 ms, accompanied by an unchanged a-wave, suggests that OFF activity may contribute to the short-duration blue-flash b-wave. It is also those patients in whom there is the presence of possible offset-related responses at the cessation of the 200-ms stimulus. Equally, those patients in whom there was no apparent OFF activity showed no reduction in b-wave amplitude when stimulus duration was increased. Similar findings have been reported,26 and the current data confirm and extend those observations. In normal retina, L- and M-cone transmission at a postreceptoral level takes place through both ON (depolarizing)- and OFF (hyperpolarizing)-bipolar cells. Foveal S-cones may contact S-cone OFF midget bipolar cells43 but rods and peripheral S-cones are thought to connect only to ON-bipolar cells.44 The existence of possible OFF-related ERG activity in most patients, albeit atypical, may suggest that the short-wavelength–sensitive cone system in ESCS transmits information in a manner more usually associated with L- and M-cones than with the classic S-cone pathway. This may reflect a default pathway from L/M-cone differentiation; may be the result of atypical second-order neuronal networks, such that S-cones synapse with both ON- and OFF-bipolar cells; or may be secondary to replacement of L- and M-cone opsins by short-wavelength–sensitive opsin.
The absence of rods in ESCS is now better understood. NR2E3 has exclusively been localized to the nuclei of rods in mature human, mouse, and zebrafish retina and is also detectable during retinal development.15 16 NR2E3 has recently been shown to have a transcriptional repressive effect on cone-specific genes in rod photoreceptors.16 Functional inactivation of NR2E3 could result in the failure of rods and photoreceptors to develop that adopt an S-cone phenotype, leading to the increased number of S-cones seen in ESCS at the expense of rod photoreceptors.16 The cause of the slow retinal degeneration observed in ESCS is more difficult to explain, but may include the inability of cone cells to survive in the absence of rod photoreceptors.45 46 Currently, less is understood about cone cell differentiation. How NR2E3 mutations result predominantly in an increased S-cone population is not established.
Mutations in NR2E3 were identified in 12 of the 13 patients who consented to give blood. Eight sequence variants in the coding region were found that most likely represent disease-causing mutations. Four of these are novel: two splice acceptor mutations, at introns 1 and 8, respectively, and two missense mutations, Val49Met and Tyr81Cys. The first novel splice site mutation (C
G nucleotide change) is located at the same intron 1 splice acceptor site previously identified as harboring one of the most common sequence variations in ESCS, that being an A
C change present in
35% to 50% of subjects.6 8 In the present study this A
C change was similarly frequently identified in
45% of subjects screened. The second novel splice acceptor mutation is at intron 8 (G
A change). A region not previously identified as harboring potentially disease-causing sequence variants. The splice acceptor introns 1 and 8 mutations would both be predicted to cause aberrant splicing, resulting in either a truncated nonfunctional protein, or one of significantly reduced transcriptional activity since exons 2 and 9 encode residues involved in DNA-binding and ligand-binding, respectively. The splice acceptor intron 1 mutation would also result in a frameshift and premature stop codon in exon 3, if exon 2 was deleted, with the resultant transcript most likely undergoing nonsense-mediated mRNA decay. The subject homozygous for the splice acceptor mutation in intron 8 has a mild phenotype, which may reflect her young age or may indicate that this splice site mutation has a less severe effect on receptor function, being located at the last coding exon, and thus predicted to affect only the terminal portion of the ligand-binding domain. The novel mutations V49M and Y81C are both located in the highly conserved DNA-binding domain of NR2E3. The subject homozygous for the V49M mutation has milder disease than other members of the panel. This mutation is located at the start of the proposed DNA-binding domain, whereas Y81C is in the central region of this domain. The individuals with the Y81C mutation were compound heterozygotes, thereby precluding a direct comparison; however, they were more severely affected, suggesting that the V49M may have a less adverse effect on DNA-binding. T161fs (481delA) will generate a premature stop codon at position 178 and is therefore the only nonsense mutation described in ESCS to date, having been identified in the homozygous state in this study and previously as a heterozygous change.8 This 1-bp deletion will most likely undergo nonsense-mediated mRNA decay. However, if this allele were translated, the truncated protein would lack the ligand-binding domain and would be nonfunctional. Therefore, whatever the precise molecular outcome of this mutation, it is likely that subjects homozygous for it would have a more severe phenotype than would heterozygous individuals. The previous report does not provide sufficient clinical data to enable such a comparison, although the two brothers in the present panel with this homozygous mutation have a relatively severe phenotype at a young age compared with other subjects.
No disease-causing sequence variants were identified in one patient with typical clinical and electrophysiological signs of ESCS, and only a heterozygous mutation was detected in another subject. It may be that the mutations in these cases are intronic, in the promoter, or present in as yet unidentified exons. In addition, heterozygous deletions may also have been missed by direct sequencing; Southern blot analysis or quantitative PCR may be useful techniques in identifying individuals with such deletions. It also cannot be absolutely excluded that there is further genetic heterogeneity to be identified, with candidate genes including NRL and THRB1.6 47 48 Although the four novel mutations identified in this study and other previously described mutations6 7 8 appear likely to be disease-causing on the basis of either aberrant splicing or location at highly conserved domains critical to protein function, only functional studies assessing the effects of these sequence variants on NR2E3 stability, targeting, and ability to interact effectively and reversibly with either DNA or ligand, can provide definitive supportive evidence of pathogenicity.
In conclusion, patients with ESCS exhibit a variable clinical phenotype associated with various degrees of pigmentary change, foveal schisis, and visual loss. The presence of pathognomonic electrophysiological responses establishes the diagnosis and directs appropriate genetic screening and counseling. Uncertainties remain concerning the nature of the electrophysiological signaling in the retinas of these patients.
| Footnotes |
|---|
Supported by EVI-Genoret FP6 Integrated Project LSHG-CT-2005-512036, British RP Society, and a Career Development Award from Foundation Fighting Blindness (IA).
Submitted for publication December 20, 2005; revised June 30, 2006, and March 5, 2007; accepted March 25, 2008.
Disclosure: I. Audo, None; M. Michaelides, None; A.G. Robson, None; M. Hawlina, None; V. Vaclavik, None; J.M. Sandbach, None; M.M. Neveu, None; C.R. Hogg, None; D.M. Hunt, None; A.T. Moore, None; A.C. Bird, None; A.R. Webster, None; G.E. Holder, None
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: Graham E. Holder, Department of Electrophysiology, Moorfields Eye Hospital, 162 City Road, London EC1V 2PD, UK; graham.holder{at}moorfields.nhs.uk.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
D. Bandah, S. Merin, M. Ashhab, E. Banin, and D. Sharon The Spectrum of Retinal Diseases Caused by NR2E3 Mutations in Israeli and Palestinian Patients Arch Ophthalmol, March 1, 2009; 127(3): 297 - 302. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |